Anticancer research · 2005
Antiprostasome antibody titres in benign and malignant prostate disease.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Minelli Alba, Ronquist Gunnar, Carlsson Lena, Mearini Ettore, Nilsson Ove, Larsson Anders
Аннотация
BACKGROUND: Prostasomes are secretory granules synthesized, stored and secreted by normal and neoplastic human prostate epithelial cells and by prostate cancer metastasis. Prostasomes are postulated to be shed into the blood circulation in prostate cancer patients, where they may cause an immune response.
MATERIALS AND METHODS: An antiprostasome antibody ELISA was developed and used to measure serum antibody titres in 81 males with prostate cancer or benign prostate hyperplasia.
RESULTS: Patients with biopsy-verified prostate cancer had significantly higher antibody titres [p = 0.019 for the dominant tumour expression (first Gleason parameter) and p = 0.022 for the dominant and non-dominant form (first and second Gleason parameters)] than individuals with benign prostate hyperplasia or other benign prostate disorders. No correlation existed between antibody titres and PSA values.
CONCLUSION: These results indicate that the antiprostasome antibody titre in serum may be a novel prostate cancer marker not replacing, but rather supplementing, PSA.
MATERIALS AND METHODS: An antiprostasome antibody ELISA was developed and used to measure serum antibody titres in 81 males with prostate cancer or benign prostate hyperplasia.
RESULTS: Patients with biopsy-verified prostate cancer had significantly higher antibody titres [p = 0.019 for the dominant tumour expression (first Gleason parameter) and p = 0.022 for the dominant and non-dominant form (first and second Gleason parameters)] than individuals with benign prostate hyperplasia or other benign prostate disorders. No correlation existed between antibody titres and PSA values.
CONCLUSION: These results indicate that the antiprostasome antibody titre in serum may be a novel prostate cancer marker not replacing, but rather supplementing, PSA.